Regeneron Pharmaceuticals Inc (REGN)

Regeneron Pharmaceuticals Inc (REGN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $82.9B; returns 1 day -1.7%, 1 week +1.8%, 1 year +39.8%.

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The company's business model is centered on its proprietary VelociSuite® technologies, a suite of advanced drug discovery and development platforms that enable the rapid generation of optimized, fully human antibodies.

Groups REGN belongs to

• Dividend Payers
• Healthcare
• Shrinking Share Count
• Biotechnology
• Buying Back Stock
• S&P 500
• Biopharmaceutical
• Pharmaceuticals
• Life Sciences
• Monoclonal Antibodies
• Ophthalmology
• Autoimmune Diseases
• Oncology
• Commercial Stage
• Drug Discovery
• R&D

REGN financial model: income statement, cash flow and balance sheet